Amgen, Finally Some Good News (AMGN, MRK)

Health and Healthcare

Published: May 19, 2008 4:01 pm

Last Updated: March 26, 2020 12:17 pm

Shares of Amgen Inc. (NASDAQ: AMGN) are seeing a small gain in after-hours trading.

The troubled biotech giant announced that findings from its head-to-head, double-blind trial comparing the effects of denosumab in post-menopausal women with low bone mass transitioned from weekly alendronate (FOSAMAX(R)) versus continued alendronate therapy on bone mineral density (BMD). This study was a one-year non-pivotal Phase III study and it demonstrated superior results for the primary and all secondary endpoints.

The primary endpoint was in the total hip and it was listed as 80% greater in the group. This was a twice-yearly subcutaneous injection in a double-blind group of 504 women who suffered from low BMD.

FOSAMAX is an osteoporosis drug from Merck & Co. (NYSE: MRK).

Jon C. Ogg
May 19, 2008

Jon Ogg produces and edits the "10 Stocks Under $10" newsletter and he does not own securities in the companies he covers.

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.